title: Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models.
abstract: We have investigated novel vaccine strategies against severe acute respiratory syndrome (SARS) CoV using cDNA constructs encoding the structural antigens: (S), (M), (E), or (N) protein, derived from SARS CoV. PBL from healthy human volunteers were administered i.p. into IL-2 receptor gamma-chain disrupted SCID mice, and SCID-PBL/hu mice were constructed. These mice can be used to analyze the human immune response in vivo. SARS M DNA vaccine and N DNA vaccine induced human CTL specific for SARS CoV antigens. Alternatively, SARS M DNA vaccines inducing human neutralizing antibodies and human monoclonal antibodies against SARS CoV are now being developed. These results show that these vaccines can induce virus-specific immune responses and should provide a useful tool for development of protective and therapeutic vaccines.
authors.affiliation: Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591-8555, Japan. okm@kch.hosp.go.jp
authors.forename: Masaji
authors.initials: M
authors.lastname: Okada
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Okuno
authors.forename: Satomi
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kita
authors.forename: Noriko
authors.initials: N
authors.lastname: Kanamaru
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Nishida
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Tsunai
authors.forename: Ruriko
authors.initials: R
authors.lastname: Inoue
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nakatani
authors.forename: Reiko
authors.initials: R
authors.lastname: Fukamizu
authors.forename: Yumi
authors.initials: Y
authors.lastname: Namie
authors.forename: Junko
authors.initials: J
authors.lastname: Yamada
authors.forename: Kyoko
authors.initials: K
authors.lastname: Takao
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Asai
authors.forename: Ryoko
authors.initials: R
authors.lastname: Asaki
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Kase
authors.forename: Yuji
authors.initials: Y
authors.lastname: Takemoto
authors.forename: Shigeto
authors.initials: S
authors.lastname: Yoshida
authors.forename: J S M
authors.initials: JS
authors.lastname: Peiris
authors.forename: Pei-Jer
authors.initials: PJ
authors.lastname: Chen
authors.forename: Naoki
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Tatsuji
authors.initials: T
authors.lastname: Nomura
authors.forename: Isao
authors.initials: I
authors.lastname: Ishida
authors.forename: Shigeru
authors.initials: S
authors.lastname: Morikawa
authors.forename: Masato
authors.initials: M
authors.lastname: Tashiro
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Sakatani
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D007116:Immunization, Passive / Q000379:methods*; D007167:Immunotherapy; D051379:Mice; D016513:Mice, SCID; D045473:Severe acute respiratory syndrome-related coronavirus / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism; D045169:Severe Acute Respiratory Syndrome / Q000517:prevention & control*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics; D014765:Viral Vaccines / Q000008:administration & dosage*
chemical_list: D019444:Vaccines, DNA; D014765:Viral Vaccines